Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.

Experimental hematology - 1 Oct 2007

Kancha Rama Krishna, Grundler Rebekka, Peschel Christian, Duyster Justus

Abstract excerpt

OBJECTIVE: Activating mutations in FLT3 are known to be a frequent transforming event in acute myeloid leukemia. Small molecule-inhibitor therapy targeting the FLT3 kinase is, therefore, an attractive strategy. FLT3 kinase inhibitors, such as PKC412, have already entered clinical trials. Even though results are encouraging, emergence of primary and secondary resistance does occur in the majority of patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Pyrroles

Share to Sorafenib

Share to Staurosporine

Share to Sunitinib

Source

Identifiers

PMID: 17889720
DOI: 10.1016/j.exphem.2007.07.008

Genes

FLT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.PMID 17889720Read ↗

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.Semantic proximity Read ↗

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Semantic proximity Read ↗

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Semantic proximity Read ↗

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.Semantic proximity Read ↗

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.Semantic proximity Read ↗

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Semantic proximity Read ↗

Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.